Aim: In Australia, the National Cervical Screening and HPV Vaccination Programs aim to reduce the incidence of cervical cancer. Identification and treatment of preinvasive disease is important, but excisional treatment has been associated with adverse pregnancy outcomes. A national quality improvement program (Cervical Quality Improvement Program [c-QuIP]) aimed to reduce the rate of excisional treatment in young human papilloma virus (HPV)-vaccinated women. This study examined national trends in the rate of excisional treatment in young women. Methods: Comprehensive national data were obtained from Medicare Australia regarding incidence rates of excisional treatment for the 10-year period 2007 to 2016 inclusive. These data were used to calculate agestratified incidence rates of excisional treatment in young (20-24 years), intermediate (25-34 years) and older (35-60 years) women. Results: The rate of excisional treatment (procedures per 10 000 women) fell in young women (from 25 to 6/7, P < 0.005) and women of intermediate age (from 23 to 13, P < 0.005), but there was no significant change in the rate in women aged 35 to 60 years (from 7 to 6.5). Conclusion: In the decade since introduction of the National HPV Vaccination Program the rate of excisional treatment of the cervix in Australia has fallen in women aged less than 35 years but has not changed for older women. The introduction of a national program aiming to reduce the rate appeared to have little impact.
Introduction
Excisional treatment for premalignant cervical dysplasia (primarily loop excision, but also cone biopsy) has an important role in prevention of invasive cervical cancer. However, loop excision is associated with increased risks of preterm birth 1 and second trimester miscarriage. 2 The increase in risk of preterm birth is increased irrespective of the histopathology being treated and is highest after repeat procedures. 3 Cervical cancer is the third most common gynecological cancer in Australia, and virtually all cases result from infection with human papilloma virus (HPV). 4, 5 For more than 20 years Australia has had a Federal Government-funded National Cervical Screening Program (NCSP) that has been associated with a 50% reduction in both the incidence and mortality of cervical cancer, and this program has now been changed to include oncogenic HPV testing as the primary population screen. 4, 6 To further reduce the incidence of cervical cancer, a Federal Governmentfunded population-based National HPV Vaccination Program (NHVP) commenced in Australia in 2007. This program provides the full course of the quadrivalent HPV vaccine Gardasil to schoolgirls aged 12-13 years. 6 This program has consistently seen more than 70% of schoolgirls immunized (see Table 1 ).
As Australian women have had access to HPV vaccination for a decade, the Australian Federal Government aimed to reduce potential overuse of excisional treatment in good-prognosis younger women. To accomplish this, the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) received funding for a national quality improvement and audit program known as the c-QuIP (Cervical Quality Improvement Program). 8, 9 The program commenced in 2012 and virtually all colposcopists in Australia participated in the program, providing mandatory audit data on the histology of excisional treatments and undergoing specific training programs. The crude rate of histologically confirmed high-grade lesions is presented in Table 2 .
Despite this national program aimed at reducing the use of excisional cervical treatments in young nulliparous women, an analysis of national data suggested that the program's aims had not been achieved. 10 The national guideline for management of cervical abnormalities was published in 2005. Its revision was published in 2017. The entire period in question utilized the same national guideline. At the end of the first year of the national c-QuIP in 2013, rates of excisional treatment in all age groups were found to be unchanged. However, the initial audit cycle for the c-QuIP lasted 3 years and is now complete. We sought to update these data and determine whether there had been a change in the rate of excisional treatment in young women by the end of the first 3-year audit cycle.
Methods
Australia has no single database for inpatient (daystay and admitted) and outpatient (office) procedures. We interrogated two datasets to identify the procedures in question. The Australian Institute of Health and Welfare (AIHW) national procedural dataset is collected under the auspice of the Australian Health Ministers' Advisory Council through the National Health Information Agreement.
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These data provide information about procedures performed on admitted patients in hospitals and day surgery facilities. We searched for all procedures coded 35647-00 (large loop excision of the transformation zone).
The second source was the Medicare data from the Medical Benefits Scheme (MBS) billing dataset. This captures excisional procedures performed in nonadmitted patients. The MBS billing data report procedural services that are performed by a registered provider for services that qualify for Medicare benefit, and for which a claim has been processed by Medicare Australia. Thus, these are complementary data to the AIHW, capturing both inpatient procedures and outpatient procedures billed through Medicare. The MBS dataset does not include services provided by hospital doctors to public patients in public hospitals (procedures captured in the AIHW dataset), or services that qualify for a benefit under the Department of Veterans' Affairs National Treatment Account. We The year 2007 was selected as the starting date as the NHVP was rolled out in that year.
The extracted data were entered into Excel (Microsoft, 2017) spreadsheets for analysis, with regressions performed and calculation of R 2 and P values. This study received approval from the Australian National University Human Research Ethics Committee (protocol 2015/347).
Results
Following introduction of the c-QuIP there was a 51% reduction in the incidence rate of loop excision in women aged 20-24 years (from 13.8 per 10 000/year to 6.8 per 10 000/year, P < 0.005) between 2012 and 2016. (Fig. 1) . However, there had already been an equivalent reduction (45%, from 25 per 10 000/year to 13.8 per 10 000/year, P < 0.005) from 2007 to 2012. Introduction of the c-QuIP did not affect the trajectory of loop-excision incidence rates. Similarly, for women aged 25-34 years, there was a 22% reduction between 2007 and 2012 (from 23 per 10 000/year to 18 per 10 000/year, P < 0.005) followed by a further reduction of 28% (from 18 per 10 000/year to 13 per 10 000/year, P < 0.005) (Fig. 2) . In contrast, there was no change in the rate of loop excision in women aged 35-59 years over the 10-year study period, and this was not affected by introduction of the c-QuIP (2007-2012, P = 0.77 and 2012-2016, P = 0.27). (Fig. 3) .
Discussion
The c-QuIP was introduced nationally to Australia to provide quality assurance in colposcopy, and one of its principal aims was to reduce the rate of excisional treatment in young women with a good prognosis. Although an early study suggested that this aim had not been met, 10 our new data covering the entire span of the first 3-year cycle confirm that excisional treatments in young women have halved at a national level. 10 It is important to note, though, that a reduction in the rate of excisional treatments had already commenced after introduction of NHVP and that the c-QuIP did not alter that trajectory. An existing trend to reduction in women aged 25-34 years accelerated after the introduction of c-QuIP, and there was no change at all for older women. It would be expected that a better trained and more rigorously audited clinicians would have a flow on effect to the level of excision in older age groups. Although not conclusive, this result supports our hypothesis that the reduction in excision is based on decreased incidence due to vaccination, rather than the c-QuIP. Weaknesses of this study are the lack of availability of contemporaneous and comprehensive national data for admitted patient care, and the fact that it has not been possible to examine the use of ablation treatments (such as radical diathermy or laser).
There are two important considerations in Australia at this point. From 2018 the Australian NCSP has changed from a cytology-based to an oncogenic HPVbased program. 13 The effect this change will have on colposcopy and excisional treatment of dysplasia remains unclear. The other consideration is that the rate of high-grade cervical dysplasia continues to decrease in young women, and this will confound interpretation of rates of excisional treatment and the effect of any quality improvement program. 7 Although rates of excisional treatment in younger women with a good prognosis are clearly important, more important is that the rate of excisional treatment for low-grade dysplasia is low. 10 Data collection is an important element of the new cervical screening program in Australia and relevant data will likely provide these data and will become available over the next 3-5 years.
Concerns about the overuse of excisional treatment in young nulliparous women with a good prognosis were among the principal drivers of the introduction of c-QuIP in Australia. 8 Loop excision increases the risk of preterm birth 1 and second trimester miscarriage 2 and is highest after repeat procedures. 3 Young women with high-grade dysplasia often have other risks predisposing them to preterm birth.
14 Women are more likely to have a shorter mid-trimester cervical length if they have undergone cervical excision, 15 although whether depth or volume of tissue excised influences the risk of preterm birth remains unresolved. Conflicting studies indicate a both direct relationship between the amount of tissue removed 1 as well as the association being a consequence of confounding, not a direct result of treatment. 16 It is clear that large excisions -thicker than 1.2 cm and larger than 6 cm 3 -are associated with a three times greater risk for preterm birth. 17 There is also an association with the interval between excisional treatment and conception, and adverse pregnancy outcomes. 18, 19 At this stage there does not appear to be any evidence that treatment for cervical intraepithelial neoplasia adversely affects fertility 2 or results in other adverse pregnancy outcomes. 20 Human papilloma virus vaccination programs in developed countries have resulted in significant population-level reductions in the incidence of highgrade squamous cervical dysplasia in young women, although this might also reflect uptake of screening. 21 A population study from Denmark, where participation in cervical screening is high, showed an increasing incidence of adenocarcinoma in young women but a reduction of invasive squamous carcinoma in older women. 22, 23 A similar study from Canada examined the rates of cervical dysplasia before and after introduction of an HPV vaccination program and reported a significant reduction in high-grade squamous lesions in young women despite vaccine uptake levels below 70%. 24 The effect of vaccination on the rate of excision would be expected to plateau as all of the women going through that age group become immunized and the population burden of disease falls. Although it is possible that the cQuIP continued the downward trend that had commenced prior to its inception, it is unlikely to have maintained it along the same trajectory.
The Australian NCSP has now changed to an oncogenic HPV-based system with a longer interscreening interval. 25 Associated changes to data recording for colposcopy-based treatments will provide detailed information about individual management. Ensuring appropriate use of excisional treatments, with lower rates for younger HPV-vaccinated women with a good prognosis and higher rates for older unvaccinated women, will require close surveillance, audit and ongoing education.
